Working...
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 8 of 699 for:    dry mouth

A Trial Looking at Treating Dry Mouth After Radiotherapy for Head and Neck Cancer (LEONIDAS-2)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT02941276
Recruitment Status : Completed
First Posted : October 21, 2016
Last Update Posted : May 18, 2017
Sponsor:
Information provided by (Responsible Party):
University College, London

Brief Summary:
This trial is looking at using an intra-oral electrostimulating device for the management of radiotherapy-induced dry mouth.

Condition or disease Intervention/treatment Phase
Xerostomia Head and Neck Neoplasms Device: Active Electrostimulator device Device: Sham Electrostimulator device Phase 3

Detailed Description:
Dry mouth is a common complaint of radiotherapy for cancer of the head and neck region. It is a distressing often persistent condition which can lead to longlasting oral discomfort, dental infections, diminished quality of life, social isolation and loneliness. Unfortunately, current therapies of dry mouth are often unsatisfactory, expensive and may result in adverse effects. A novel intraoral electronic device has recently been developed to treat dry mouth. The device, acting as a "salivary pacemaker", harmlessly stimulates nerves of the salivary glands and does not cause adverse side effects. The aim of this proposal is to assess the longterm effects of such a device in this population, which have yet to be investigated, to demonstrate whether its daily application is an effective method of lessening dry mouth and improving life quality. 84 individuals will be enrolled in the study to use the device for 12 months, after receiving appropriate instructions. 42 participants (out of 84) will act as controls as they will receive a sham device that will not deliver electric stimuli but only tactile stimulation (like using a chewing gum). All participants will be allowed to continue using their routine local therapy for dry mouth (e.g. artificial saliva) during the study. Each participant will keep a diary relevant to the frequency of use and potential changes in dry mouth sensation. Participants will also be asked to attend hospital appointments to measure changes in saliva production and complete questionnaires on their dry mouth and quality of life. The device has the potential to radically change current clinical practice. If the trial is successful, the use of the device will provide patients having radiation-induced dry mouth with a safe and drug-free therapeutic modality.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 84 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Triple (Participant, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: Long-term Evaluation of the Effectiveness Of a Novel Intra-oral Electro-stimulator for the Treatment of raDiotherapy-ASsociated Dry Mouth
Study Start Date : November 2011
Actual Primary Completion Date : November 2014
Actual Study Completion Date : November 2014

Resource links provided by the National Library of Medicine


Arm Intervention/treatment
Experimental: Group A
Active electrostimulator device
Device: Active Electrostimulator device
Patients who will receive a fully functioning device

Sham Comparator: Group B
Sham electrostimulator device
Device: Sham Electrostimulator device
Patients who will receive a device that does not release electric stimuli (but provided mechanical/tactile stimulation)




Primary Outcome Measures :
  1. Improvement of subjective perception of dry mouth as measured on the Visual Analog Scale [ Time Frame: 12 month ]
    The primary outcome is defined as the proportion of patients reporting a 30% reduction of xerostomia symptoms as evaluated through a 100mm VAS (100mm=maximum dryness).


Secondary Outcome Measures :
  1. Improvement of objective salivary function as measured through 5-minutes sialometry [ Time Frame: 12 month ]
  2. Improvement in head and neck quality of life as measured on the EORTC QLQ-H&N35 [ Time Frame: 12 month ]
  3. Improvement in oral health quality of life as measured on the OH-QoL16 questionnaire [ Time Frame: 12 month ]
  4. Improvement in general quality of life as measured on the SF-36 questionnaire [ Time Frame: 12 month ]
  5. Evaluation of patients' tolerance in using the device by using a diary to record daily measurement. [ Time Frame: 12 month ]


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. To be at least 18 years old
  2. To have received more than 40 Gy of external beam RT for cancer in the H&N region at least 4 months before entry into the study
  3. To have grade 1 or 2 of RTOG/EORTC Late Radiation Morbidity Scoring Schema
  4. To have a degree of minimum degree of dryness of 50mm (≥50mm) on a 100mm VAS scale (0=no dryness; 100

    =maximum dryness).

  5. To have demonstrable residual salivary gland function (increase in salivary flow on appropriate stimulation (e.g. chewing paraffin wax)
  6. To have at least one parotid gland

Exclusion Criteria:

  1. To have severe uncontrolled systemic disease (on the basis of the classification of the American Society of Anesthesiology: ASA IV and ASA V)
  2. To have known allergy to materials similar to those used in the investigational product
  3. To wear other active implants such as cardiac pacemaker or defibrillator, or hearing aids
  4. To have an unstimulated whole salivary flow of 0ml/15min (complete absence of unstimulated salivary flow as measured via sialometry for 15 minutes).
  5. To use of pilocarpine as systemic therapy
  6. To have grade 3 RTOG/EROTC or no resting saliva (sialometry = 0mL/1.5 min)
  7. To have no parotid glands

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02941276


Sponsors and Collaborators
University College, London
Investigators
Layout table for investigator information
Principal Investigator: Dr Stefano Fedele, PhD University College, London

Layout table for additonal information
Responsible Party: University College, London
ClinicalTrials.gov Identifier: NCT02941276     History of Changes
Other Study ID Numbers: 11/YH/0072
First Posted: October 21, 2016    Key Record Dates
Last Update Posted: May 18, 2017
Last Verified: May 2017
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: Yes
Plan Description: Research manuscript in preparation.

Additional relevant MeSH terms:
Layout table for MeSH terms
Xerostomia
Head and Neck Neoplasms
Salivary Gland Diseases
Mouth Diseases
Stomatognathic Diseases
Neoplasms by Site
Neoplasms